Skip to main content
Figure 1 | Journal of Experimental & Clinical Cancer Research

Figure 1

From: DNA Methylation status of Wnt antagonist SFRP5 can predict the response to the EGFR-tyrosine kinase inhibitor therapy in non-small cell lung cancer

Figure 1

Hierarchical clustering of Wnt antagonist DNA methylation status and EGFR genotype in 155 patients received EGFR-TKI therapy. Red represents methylated gene or mutated EGFR, while blue represents unmethylated gene or wild-type EGFR, The figure of hierarchical clustering showed that the epigenotype of Wnt antagonist genes had similar patterns, which were different from the genotype of EGFR.

Back to article page